1. Home
  2. LH vs UTHR Comparison

LH vs UTHR Comparison

Compare LH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LH

Laboratory Corporation of America Holdings

N/A

Current Price

$324.09

Market Cap

25.9B

Sector

Health Care

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$502.60

Market Cap

23.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LH
UTHR
Founded
1971
1996
Country
United States
United States
Employees
70000
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9B
23.1B
IPO Year
2005
1999

Fundamental Metrics

Financial Performance
Metric
LH
UTHR
Price
$324.09
$502.60
Analyst Decision
Buy
Buy
Analyst Count
9
14
Target Price
$311.33
$567.57
AVG Volume (30 Days)
657.6K
460.9K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
1.12%
N/A
EPS Growth
18.33
13.07
EPS
6.99
13.07
Revenue
$13,951,700,000.00
$1,483,300,000.00
Revenue This Year
$8.26
$6.39
Revenue Next Year
$4.81
$14.18
P/E Ratio
$46.35
$38.28
Revenue Growth
7.25
2.38
52 Week Low
$244.52
$397.00
52 Week High
$341.80
$609.35

Technical Indicators

Market Signals
Indicator
LH
UTHR
Relative Strength Index (RSI) 52.98 44.40
Support Level $251.43 $492.57
Resistance Level $341.80 $538.77
Average True Range (ATR) 8.42 14.67
MACD -3.03 0.20
Stochastic Oscillator 50.96 42.63

Price Performance

Historical Comparison
LH
UTHR

About LH Laboratory Corporation of America Holdings

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: